At DFCI, she has initiated an integrated program of research and clinical activities that focuses on dissecting the underlying mechanisms of pathobiology of chronic lymphocytic leukemia (CLL) as a means to more rationally generate effective therapies, including immune-based treatments, for this common adult leukemia. Through large-scale genome analysis of chronic lymphocytic leukemia, her laboratory has discovered key mutated genes and pathways involved in CLL. Ongoing studies in her laboratory focus on systematically analyzing tumor genotype – phenotype relationships, understanding CLL tumor heterogeneity and clonal evolution; and mechanistically dissecting the impact of novel CLL driver genes.